Mays Cancer Center Led Studies Of Innovative Breast Cancer Drug That Recently Gained FDA Approval
February 02, 2023
February 02, 2023
SAN ANTONIO, Texas, Feb. 2 (TNSres) -- The University of Texas Health Science Center at San Antonio issued the following news release:
The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer. The U.S. Food and Drug Administration on Jan. 27 announced it approved . . .
The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, was the lead site for a study evaluating Phase I and Phase III clinical trials for elacestrant, a treatment for postmenopausal women and adult men with ER+/HER2- advanced or metastatic breast cancer. The U.S. Food and Drug Administration on Jan. 27 announced it approved . . .